Evidence map›Paper›PMID 40446218›Full record

ArticleAmerican journal of respiratory cell and molecular biology2025

Pulmonary Fibrosis-Focusing on the Future: Aspen Lung Conference 2024 Summary.

Margaret A T Freeberg, Elizabeth F Redente, Apostolos Perelas, David W H Riches, David A Schwartz, Patricia J Sime

Abstract readConference Proceedings
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Margaret A T FreebergDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0001-7301-7880
Elizabeth F RedenteProgram in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado.ORCID 0000-0002-8075-4325
Apostolos PerelasDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
David W H RichesProgram in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado.
David A SchwartzDepartment of Medicine, Anschutz School of Medicine, University of Colorado, Aurora, Colorado; and.ORCID 0000-0001-6743-8443
Patricia J SimeDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0002-5101-634X

Funding

Targeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH3HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$4.8M
Molecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH2HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2014 to 2015
$3.0M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of ResolutionR01HL147860 · NHLBI · NATIONAL JEWISH HEALTH · PI REDENTE, ELIZABETH FRANCES · 2019 to 2023
$2.7M
Activation of matrix metalloproteinase-9 is essential to overcome failed fibrosis resolutionR01HL173030 · NHLBI · NATIONAL JEWISH HEALTH · PI Elizabeth Frances Redente · 2024 to 2026
$2.0M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUG3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2020 to 2021
$1.7M
Mechanotransduction regulation of cellular metabolism in pulmonary fibrosisK99HL169903 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI THOMAS FREEBERG, MARGARET · 2024 to 2024
$171k
Aspen Lung Conference Pulmonary Fibrosis - focusing on the futureR13HL174110 · NHLBI · NATIONAL JEWISH HEALTH · PI REDENTE, ELIZABETH FRANCES, SCHWARTZ, DAVID ALBERT · 2024 to 2024
$30k
BLRD VA I01 BX003471BLRD VA I01 BX005295NHLBI NIH HHS 1R13HL174110-01NHLBI NIH HHS K99 HL169903NHLBI NIH HHS P01 HL162607NHLBI NIH HHS R01 HL147860NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL158668NHLBI NIH HHS R01 HL173030NHLBI NIH HHS R13 HL174110NHLBI NIH HHS UG3 HL151865NHLBI NIH HHS UH2 HL123442NHLBI NIH HHS UH3 HL123442
6 · The paper itself

Abstract

As medical and scientific communities, we have enjoyed exciting advances in our mechanistic understanding, diagnosis, and therapy of different types of lung fibrosis. However, much still needs to be learned as we are challenged to make earlier diagnoses; improve our ability to assess active disease and risks for disease progression; advance our understanding of the complex interplay of molecular, genetic, and cellular cross-talk processes that underly the disease; and develop transformative therapeutic options to treat and prevent progressive lung fibrosis. Elucidating cellular phenotypes, function and signaling, and the interplay with matrices and aspects of mechanobiology has the potential to help us identify future targets and even reprogram or rebuild a damaged lung. Key to potential future opportunities will be understanding what aspects of fibrogenesis can be prevented or reversed. Bringing together a group of respected medical and scientific thought leaders, the 66th Annual Thomas L. Petty Aspen Lung Conference was titled "Pulmonary Fibrosis-Focusing on the Future." The conference topics included concepts and technologies for identification of early disease and progression using imaging and -omics approaches, identifying and understanding cellular phenotypes and their function, and cross-talk between different cell types, matrices, and matrix receptors. A central theme throughout was the integration of these scientific advances to advance novel targets for therapy, including aspects of reprogramming and rebuilding a damaged lung. The conference provided a forum for discussion, debate, and exchange of ideas with leaders and trainees in the field with the goal to help advance our shared mission of preventing and curing pulmonary fibrotic disease.

Indexed as

LungPulmonary FibrosisAnimalsDisease ProgressionHumansbiomaterialsepithelial cellsfibroblastsmolecular imagingpulmonary fibrosis

Identifiers

PMID40446218
PMCPMC12618867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.